EHA 2023 again featured a plethora of interesting oral abstracts and poster presentations in the field of acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). In this article, we will highlight some of the most promising data with regard to AML clinical studies, novel combinations in the treatment of AML and risk stratification. Furthermore, we will discuss some important clinical updates in the field of MDS.
(BELG J HEMATOL 2023;14(5):221–5)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
